A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
The main goal of this study is to evaluate the stability of molecular response (major and
 deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with
 stable DMR after two-stage dose reduction phase and discontinuation treatment TKI: imatinib,
 nilotinib, dasatinib and bosutinib.
The duration of the dose reduction phase will be 12 months. This phase will have two stage of
 6 months, respectively.

 The dose of imatinib, nilotinib, dasatinib or bosutinib will be reduced by 25-50% on the
 first stage, and by another 25% on the second stage.

 -  The initial dose of imatinib will be 400 mg daily. The dose will be reduced by 300 mg
 daily on the first stage, by 200 mg daily - on the second stage.

 -  The initial dose of nilotinib will be 300 or 400 mg twice daily. The dose will be
 reduced by 400 mg daily on the first stage, by 200 mg daily - on the second stage.

 -  The initial dose of dasatinib will be 100 or 140 mg daily. The dose will be reduced by
 50 mg daily on the first stage, by 25 mg daily - on the second stage.

 -  The initial dose of bosutinib will be 500 mg daily. The dose will be reduced by 300 mg
 daily on the first stage, by 200 mg daily - on the second stage.

 All patients with stable deep molecular response (at least 2 years) will be included in
 treatment free remission phase (TFR-phase). The duration of TFR-phase will be 24 months.

 The CML patients can enter the study already on reduced doses TKI, if they will meet the
 inclusion criteria.

 It is possible to include patients, who have already received therapy with reduced doses of
 TKI. The duration of TKI therapy with reduced doses of 1 stage should be at least 6 months,
 if TKI doses meet of stage 1. The duration of TKI therapy with reduced doses of 2 stage
 should be for at least 6 months and the general duration of TKI therapy with reduced doses
 should be for at least 12 months, if TKI doses meet of stage 2.
Inclusion Criteria:

 1. CML in chronic phase.

 2. TKI treatment for at least 3 years.

 3. DMR (BCR-ABL≤0.01%) for at least 1 year, MMR (BCR-ABL≤0.1%) for at least 2 years

 4. At least 3 molecular results over the preceding 24 months, which confirm the presence
 of MMR and DMR

 5. Written Informed Consent

 6. CML patients with DMR for at least 1 years and MMR for at least 2 years after STOP TKI
 in anamnesis.

 For patients who are on the reduced dose TKI (1 stage) at the time of inclusion in the
 study

 1. The duration of therapy at reduced doses of TKI phase I is at least 6 months.

 For patients on the reduced dose TKI (2 stage, before TFR phase) at the time of inclusion
 in the study

 1. DMR (BCR-ABL≤0.01%) for at least 2 years

 2. The duration of therapy at reduced doses of TKI phase 1 is for at least 6 months, the
 total duration of therapy at reduced doses is for at least 12 months.

 Exclusion Criteria:

 1. Age under 18

 2. ECOG >2

 3. CML in accelerated phase or blast crisis at any time

 4. Lack of Written Informed Consent

 5. Pregnant or lactating women

 6. Incapacity